Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Update

Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 1,900,000 shares, a drop of 12.8% from the October 15th total of 2,180,000 shares. Approximately 5.2% of the shares of the stock are sold short. Based on an average daily volume of 269,800 shares, the short-interest ratio is currently 7.0 days.

Hedge Funds Weigh In On Astrana Health

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new stake in shares of Astrana Health during the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC bought a new stake in shares of Astrana Health in the 3rd quarter worth about $35,000. KBC Group NV acquired a new stake in Astrana Health during the third quarter valued at approximately $70,000. Quarry LP bought a new stake in Astrana Health during the third quarter valued at $77,000. Finally, Quest Partners LLC acquired a new stake in Astrana Health during the third quarter worth about $133,000. Institutional investors and hedge funds own 52.77% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on ASTH. KeyCorp started coverage on Astrana Health in a research report on Friday, October 11th. They set a "sector weight" rating on the stock. Robert W. Baird boosted their price objective on shares of Astrana Health from $67.00 to $86.00 and gave the stock an "outperform" rating in a research report on Wednesday. TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They set a "buy" rating and a $66.00 target price for the company. Truist Financial lifted their target price on shares of Astrana Health from $50.00 to $59.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus upped their price objective on Astrana Health from $48.00 to $60.00 and gave the company a "buy" rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Astrana Health currently has a consensus rating of "Buy" and an average target price of $65.17.

Astrana Health Trading Down 2.6 %

Shares of ASTH stock traded down $1.09 during trading hours on Friday, hitting $40.81. 392,557 shares of the company were exchanged, compared to its average volume of 207,694. Astrana Health has a 1 year low of $32.04 and a 1 year high of $63.20. The firm has a fifty day moving average of $55.04 and a 200 day moving average of $47.74. The firm has a market cap of $2.30 billion, a PE ratio of 31.39, a PEG ratio of 1.96 and a beta of 1.24. The company has a quick ratio of 1.84, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. During the same period in the prior year, the firm posted $0.47 earnings per share. Analysts expect that Astrana Health will post 1.16 earnings per share for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.